EU probes Lundbeck for antitrust of generic sales
January 11, 2010
According to Bloomberg, Denmark’s H. Lundbeck faces a European Union antitrust investigation into whether it impedes the sale of generic versions of antidepressant drug citalopram. In a statement the European Commission in Brussels said that the probe will focus on “unilateral behavior and agreements by Lundbeck which may hinder the entry of generic citalopram” in European markets. Commission officials raided the offices of Lundbeck, Teva Pharmaceutical Industries Ltd., and other companies in December as part of an antitrust investigation. The surprise inspections marked the fourth time drugmakers’ offices have been visited since the EU started a probe of the pharmaceutical industry in January 2008. The EU has focused on whether manufacturers misuse patents and lawsuit settlements to keep cheaper generic medicines off the market.